A novel contraceptive solution is set to be introduced through a collaboration between Choice, a startup based in Eindhoven, and the French tech company SilMach. The innovative hormone-free device controls fertility by employing a microvalve within the fallopian tubes, aiming to mitigate concerns related to traditional contraceptives that often rely on hormones. The partnership underscores a significant step in the realm of female reproductive health by focusing on alternatives to methods that have not evolved significantly over the past six decades.
Choice was founded in response to the high rate of unintended pregnancies, which still account for 40% globally. The company’s CEO, Peter van de Graaf, envisions enabling women to switch their fertility on or off as needed, thus addressing the growing dissatisfaction with hormonal methods. SilMach, established in 2003, specializes in Micro-Electro-Mechanical Systems (MEMS) that span various sectors, including defense and aerospace. The integration of SilMach’s MEMS technology into Choice’s contraception aligns with a shared vision to explore practical applications of advanced microtechnology. Such endeavors reflect ongoing discussions in the field of technological developments being utilized in healthcare sectors beyond their conventional uses.
How does the microvalve work?
The microvalve technology developed by Choice targets the fallopian tubes, the primary site for controlling fertility. This entry point for intervention was determined through consultations with gynecologists and scientists. The approach involves a wirelessly controlled valve that can be permanently implanted to regulate the passage of eggs. According to van de Graaf, addressing the challenges of finding or creating a small enough motor to fit this anatomical space was pivotal. This development was realized through a collaboration that tapped into SilMach’s expertise in crafting micromotors that have applications in multiple fields.
Can SilMach’s expertise redefine contraception?
SilMach’s contributions to sectors such as aerospace and defense display their capacity for substantial technological innovation. Their background in manufacturing MEMS-based solutions and the recent engagement in improving soldier safety highlight their adaptability in addressing diverse, complex needs. CEO Pierre-François Louvigné remarked on the project’s ambition and the technical nuances involved in adapting their micromotors for contraceptive use, emphasizing that “initial concerns about motor size were resolved through detailed simulation and testing.” Their advanced micro-motors, initially designed for other high-tech applications, have been successfully tailored to meet the project requirements.
The partnership continues to adapt as they address challenges such as power delivery to the deeply implanted device, light of previous experiences like the ChronoMEMS project for the French armed forces, where traceability and reliability were paramount. Such historical insights have directed collaborative efforts toward perfecting the contraceptive device’s energy efficiency and integration, harnessing unique MEMS sensor capabilities.
The process of switching fertility is planned to be conducted in a clinical setting, involving a large external transmitter used during visits. Emphasizing its simplicity and reliability, the external device is not designed for frequent use, thereby reducing the risk of loss or misuse. Partnering with TU Eindhoven and other experts has been instrumental in overcoming technical issues like power transmission to the tiny implant.
Implementation of this device also comes with socio-political considerations. Choice’s goal is to offer new options for women who prefer non-hormonal methods, often due to adverse side effects, chronic conditions, or personal convictions. The design and future of this technology hold potential ramifications amid some countries’ shifting policies regarding reproductive rights, with Choice proposing to make specific technology elements open source to counter possible restrictions.
Choice aims to enter the market priced at approximately $2,500 for the implant, providing women in developed countries a long-term alternative that could compete financially with existing contraceptive methods over time. Looking ahead, the company anticipates the first phase of clinical testing will begin by late 2026, moving toward potential commercialization by 2032. As this endeavor progresses, van de Graaf notes the conceptual simplicity but recognizes ahead “getting it off the ground is crucial, much like early aviation endeavors.”
